Owners, management and financials
CVR: 41598263
Previous names: Glæsner & Dam ApS, GK Consult ApS, NORDICUS Partners ApS
DKK 4,853,562
Gross profit
Net result: DKK -5,521,565
Nordicus Partners Corporation (100%)
CVR · view owners
Christian Torben Hill-Madsen
Board: Peter Severin Bach (chair) and 2 members
CVR · view management
Active
Founded 12 August 2020
CVR · view overview
12 employees
CVR · 2026
Name registered: NP Bioinnovation A/S
CVR · 10/03/2025
View the full event history
NP Bioinnovation A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 2020. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named NP Communications A/S and Managementselskabet af 12.08.2020 A/S. The management consists of Christian Torben Hill-Madsen. The board consists of Peter Severin Bach (chair), Allan Traugott Wehnert and Henrik Rouf. The company is owned by Nordicus Partners Corporation. The company has 12 employees (2026). In 2026, the company reported a gross profit of DKK 4,853,562 and a net result of DKK -5,521,565 compared with DKK -60,069 the year before. Equity in the 2026 report amounted to DKK -5,353,675.
Source: annual report 2026, Danish Business Authority
The financial health of NP Bioinnovation A/S appears to be concerning, with consistent losses reported since its inception in 2020. In 2026, the company recorded a gross profit of 4,853,562 DKK but still faced a significant loss of 5,521,565 DKK, indicating challenges in achieving profitability despite some gross profit. Equity has been negative since 2025, dropping to -5,353,675 DKK in 2026, which raises concerns about its financial stability and ability to attract investment. The lack of disclosed revenue further complicates the assessment of its market position within the pharmaceutical manufacturing industry, suggesting a need for strategic improvements to enhance financial performance.
AI-generated summary · Generated 02/10/2026
Selskabets formål er at udvikle lægemidler og dermed beslægtet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202601/04/2025 – 31/03/2026 | 4.9 mio. | -5.5 mio. | 8.5 mio. | -5.4 mio. | 11 | |
| 202501/04/2024 – 31/03/2025 | -32 t. | -60 t. | 200 t. | 168 t. | 0 | |
| 202401/04/2023 – 31/03/2024 | -59 t. | -80 t. | 263 t. | 228 t. | 0 |
Compared to 129 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationThe CVR number of NP Bioinnovation A/S is 41598263.
NP Bioinnovation A/S is owned by Nordicus Partners Corporation.
The management of NP Bioinnovation A/S consists of Christian Torben Hill-Madsen.
The board of NP Bioinnovation A/S consists of Peter Severin Bach, Allan Traugott Wehnert and Henrik Rouf, with Peter Severin Bach as chair.
In 2026, NP Bioinnovation A/S reported a gross profit of DKK 4,853,562.
NP Bioinnovation A/S had 12 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
NP Bioinnovation A/S has published its annual report for 2026. Gross profit came to DKK 4,853,562, and the net result was DKK -5,521,565.
Contact info changed: new email: [email protected] (April 22, 2026).
Address changed to Vandtårnsvej 62A 1. b 62, 1 b, 2860 Søborg (February 2, 2026).
Contact info changed: new email: [email protected] (February 2, 2026).
NP Bioinnovation A/S has published its annual report for 2025. Gross profit came to DKK -32,360, and the net result was DKK -60,069.
As of September 24, 2025, Allan Traugott Wehnert has joined the board of directors of NP Bioinnovation A/S.
As of September 24, 2025, Henrik Keller has left the board of directors of NP Bioinnovation A/S.
On March 10, 2025, the company changed its name from NP Communications A/S to NP Bioinnovation A/S.
As of January 10, 2025, Peter Severin Bach has joined the board of directors of NP Bioinnovation A/S.
As of January 10, 2025, Christian Torben Hill-Madsen has left the board of directors of NP Bioinnovation A/S.
On January 10, 2025, the company changed its name from Managementselskabet af 12.08.2020 A/S to NP Communications A/S.
As of December 6, 2024, CROWE STATSAUTORISERET REVISIONSINTERESSENTSKAB has been appointed auditor of NP Bioinnovation A/S.
As of December 6, 2024, Beierholm Godkendt Revisionspartnerselskab has stepped down as auditor of NP Bioinnovation A/S.
NP Bioinnovation A/S has published its annual report for 2024. Gross profit came to DKK -59,167, and the net result was DKK -80,271.
On November 29, 2023, the company changed its name from NORDICUS Partners A/S to Managementselskabet af 12.08.2020 A/S.
NP Bioinnovation A/S has published its interim report for the period July 1, 2022 to March 31, 2023.
As of June 12, 2023, Christian Torben Hill-Madsen has joined the board of directors of NP Bioinnovation A/S.
As of June 12, 2023, Henrik Keller has joined the board of directors of NP Bioinnovation A/S.
As of June 12, 2023, Tom Glæsner Larsen has left the board of directors of NP Bioinnovation A/S.
As of June 12, 2023, Christian Torben Hill-Madsen is registered as director of NP Bioinnovation A/S.
As of June 12, 2023, Tom Glæsner Larsen has stepped down as director of NP Bioinnovation A/S.
As of June 11, 2023, Christian Torben Hill-Madsen has left the board of directors of NP Bioinnovation A/S.
As of February 22, 2023, is registered as an owner of NP Bioinnovation A/S with an ownership share of 100%.
As of November 16, 2022, Beierholm Godkendt Revisionspartnerselskab has been appointed auditor of NP Bioinnovation A/S.
As of November 16, 2022, Christian Torben Hill-Madsen has joined the board of directors of NP Bioinnovation A/S.
As of November 16, 2022, Tom Glæsner Larsen has joined the board of directors of NP Bioinnovation A/S.
As of November 16, 2022, Henrik Rouf has joined the board of directors of NP Bioinnovation A/S.
On November 16, 2022, the company changed its name from NORDICUS Partners ApS to NORDICUS Partners A/S.
NP Bioinnovation A/S has published its interim report for the period January 1, 2022 to June 30, 2022.
On October 31, 2022, the company changed its name from GK Consult ApS to NORDICUS Partners ApS.
NP Bioinnovation A/S has published its interim report for the period August 12, 2020 to December 31, 2021.
On June 9, 2022, the company changed its name from Glæsner & Dam ApS to GK Consult ApS.
As of April 13, 2022, Hans Martin Dam has stepped down as director of NP Bioinnovation A/S.
As of August 12, 2020, Hans Martin Dam is registered as director of NP Bioinnovation A/S.
As of August 12, 2020, Tom Glæsner Larsen is registered as director of NP Bioinnovation A/S.
NP Bioinnovation A/S was founded on August 12, 2020.
Companies in the same industry and area
CVR 39842319
CVR 44348845
CVR 44482096
CVR 45929345
CVR 45480941
